CPIX sentiment intelligence

Cumberland Pharmaceuticals declares $1.50 special dividend, $5M buyback after $100M Apotex deal

Cumberland Pharmaceuticals (CPIX) announced a special cash dividend of $1.50 per share and a new $5 million share repurchase program. These actions follow the closing of a $100 million strategic transaction with Apotex, which provided additional net cash. The company stated that

Tone

Positive 71/100

Event

Capital return

Published

14 Jul 2026 03:34

Source

TradingView

Cumberland Pharmaceuticals (Nasdaq: CPIX) returns cash after $100M Apotex deal

Cumberland Pharmaceuticals (CPIX) declared a special cash dividend of $1.50 per share and authorized a new $5 million share repurchase program. These actions follow the company's strategic transaction with Apotex Health Corp., which brought in $100 million in cash at closing and

Tone

Positive 71/100

Event

Capital return

Published

13 Jul 2026 21:40

Source

Stock Titan

Cumberland Pharma Board of Directors Has Authorized and Declared a Special Cash Div of $1.50 a Shr >CPIX

Cumberland Pharmaceuticals Inc.'s board of directors has authorized and declared a special cash dividend of $1.50 per share of common stock. This dividend will be payable on August 9, 2026, to shareholders of record as of July 26, 2026. The special dividend reflects the company's

Tone

Positive 77/100

Event

Capital return

Published

13 Jul 2026 16:40

Source

Moomoo

Cumberland Declares Special Dividend, Approves $5 Million Share Buyback

Tone

Positive 62/100

Event

Capital return

Published

13 Jul 2026 15:26

Source

MT Newswires

Press Release: CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Cumberland Pharmaceuticals has announced a special cash dividend of $1.50 per common share. This dividend is payable to shareholders of record as of July 29, 2026, with the payment scheduled for August 12, 2026. This announcement highlights the company's financial performance and

Tone

Positive 82/100

Event

Capital return

Published

13 Jul 2026 15:40

Source

Moomoo

$1.50-a-share cash windfall as Cumberland pivots to rare-disease drug ifetroban

Cumberland Pharmaceuticals (CPIX) declared a special cash dividend of $1.50 per share, payable on July 31, 2026, following a strategic transaction with Apotex Health that provided $100 million in cash. The company also authorized a $5 million share repurchase program and will red

Tone

Positive 71/100

Event

Capital return

Published

13 Jul 2026 14:45

Source

Stock Titan

CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced a special cash dividend of $1.50 per share following a strategic transaction with Apotex Health. The dividend will be payable on July 31, 2026, to shareholders of record on July 10, 2026. This decision, along with a $5 mill

Tone

Positive 70/100

Event

Capital return

Published

13 Jul 2026 14:45

Source

TradingView

$1.50-a-share windfall: Cumberland Pharma tags July 23 to qualify

Cumberland Pharmaceuticals (CPIX) has declared a special cash dividend of $1.50 per share, payable on July 31, 2026, to shareholders of record on July 23, 2026. This dividend follows a strategic transaction with Apotex Health, which provided Cumberland with $100 million in cash u

Tone

Positive 89/100

Event

Capital return

Published

13 Jul 2026 14:40

Source

Stock Titan

Cumberland Pharmaceuticals Announces Special Dividend, Payable on July 31, 2026

Cumberland Pharmaceuticals Inc. has declared a special cash dividend of $1.50 per share of its common stock. This dividend will be payable on July 31, 2026, to shareholders who are on record as of the close of business on July 10, 2026. This announcement comes amidst other compan

Tone

Positive 70/100

Event

Capital return

Published

13 Jul 2026 12:35

Source

www.marketscreener.com

Cumberland Pharmaceuticals (Nasdaq:CPIX) - Stock Analysis

Cumberland Pharmaceuticals Inc. (CPIX) recently saw Apotex Inc. complete the acquisition of certain assets related to pharmaceutical products for $100 million. Additionally, the company released updated positive results from its Phase 2 FIGHT DMD trial for ifetroban, a novel ther

Tone

Positive 61/100

Event

Deals and strategy

Published

06 Jul 2026 01:41

Source

Simply Wall Street

Cumberland Pharmaceuticals Sells Branded Drug Portfolio to Apotex for $100M, Refocuses on Rare Disease Pipeline 1

Cumberland Pharmaceuticals Inc. has completed a $100 million cash transaction with Apotex Health Corp., selling its branded U.S. pharmaceuticals portfolio. This move allows Cumberland to refocus its resources on developing its rare disease pipeline, including clinical-stage progr

Tone

Positive 73/100

Event

Balance sheet

Published

02 Jul 2026 02:10

Source

Minichart

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

Cumberland Pharmaceuticals announced the closing of a $100 million strategic transaction with Apotex, involving Apotex's acquisition of Cumberland's branded pharmaceutical line. This deal, strongly supported by shareholders, strengthens Cumberland's financial position, allowing i

Tone

Positive 74/100

Event

Deals and strategy

Published

01 Jul 2026 23:09

Source

Market source

Cumberland Pharmaceuticals closes $100 million sale of drug portfolio

Cumberland Pharmaceuticals has successfully closed a $100 million deal to sell a portion of its business to Apotex. This strategic move will allow Cumberland to refocus its operations. The article hints at the future direction of the Nashville-based firm following this significan

Tone

Positive 68/100

Event

Deals and strategy

Published

01 Jul 2026 19:09

Source

The Business Journals

Cumberland sells branded drug portfolio to Apotex for $100m

Cumberland Pharmaceuticals Inc. has sold its branded pharmaceutical products line to Apotex Health Corp. for $100 million in cash, following broad shareholder approval. This move allows Cumberland to strengthen its financial position and focus on developing its pipeline programs,

Tone

Positive 72/100

Event

Regulatory and legal

Published

01 Jul 2026 14:09

Source

Investing.com

Cumberland sells branded U.S. drugs to Apotex for $100M

Cumberland Pharmaceuticals (CPIX) has closed a $100 million cash transaction with an Apotex subsidiary, selling its branded U.S. pharmaceutical line after securing over 99% shareholder approval. The company will now concentrate its resources on developing ifetroban, a compound wi

Tone

Positive 70/100

Event

Regulatory and legal

Published

01 Jul 2026 13:09

Source

Stock Titan

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

Cumberland Pharmaceuticals presented updated results from its Phase 2 FIGHT DMD trial for ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy conference. The findings reinforced ifetroban's cardiopro

Tone

Positive 73/100

Event

Earnings

Published

27 Jun 2026 09:40

Source

Yahoo! Finance Canada

Cumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported positive updates from its Phase 2 FIGHT DMD trial for ifetroban, investigating its use in Duchenne muscular dystrophy (DMD) heart disease. The trial showed significant cardioprotective effects, including improved left ventri

Tone

Positive 70/100

Event

Market update

Published

26 Jun 2026 22:11

Source

Sahm

Why Is Cumberland Pharma Stock Gaining Friday? - Cumberland Pharma (NASDAQ:CPIX)

Cumberland Pharmaceuticals' stock (NASDAQ: CPIX) surged on Friday due to positive updates from its Phase 2 FIGHT DMD trial for ifetroban, a treatment for Duchenne muscular dystrophy (DMD) heart disease. The trial showed that ifetroban has cardioprotective effects, significantly i

Tone

Positive 73/100

Event

Market update

Published

26 Jun 2026 17:40

Source

Benzinga

Cumberland says updated DMD heart data strengthen ifetroban case

Cumberland Pharmaceuticals (NASDAQ: CPIX) presented updated Phase 2 FIGHT DMD trial results for ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the 2026 Parent Project Muscular Dystrophy conference. The data show that high-dose ifetroban le

Tone

Positive 71/100

Event

Earnings

Published

26 Jun 2026 14:40

Source

Stock Titan

Shareholders back Cumberland (NASDAQ: CPIX) sale of most assets

Cumberland Pharmaceuticals Inc. shareholders have approved the sale of most of the company's assets to Apotex Inc. This strategic transaction, which includes FDA-approved commercial products, was overwhelmingly supported with 70.03% of all outstanding shares voting in favor. The

Tone

Positive 63/100

Event

Market update

Published

25 Jun 2026 21:12

Source

Stock Titan